A role for coagulation factor Xa in experimental pulmonary arterial hypertension

Cardiovascular Research

Volumn 92, Issue 1, 2011, Pages 159-168

  Delbeck, Martina ^a   Nickel, Katrin F ^a   Perzborn, Elisabeth ^a   Ellinghaus, Peter ^b   Strassburger, Julia ^a   Kast, Raimund ^a   Laux, Volker ^a   Schfer, Stefan ^a   Schermuly, Ralph T ^c   Von Degenfeld, Georges ^d,e  

^a Cardiology Research   (Germany)

^b Target Discovery   (Germany)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^d Bayer HealthCare   (Germany)

^e UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Coagulation factors; Enoxaparin; Pulmonary hypertension; Rivaroxaban; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 2; CONNECTIVE TISSUE GROWTH FACTOR; ENOXAPARIN; FIBRONECTIN; MONOCROTALINE; PLACEBO; RIVAROXABAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD CLOTTING; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FIBRINOLYSIS; HEART HEMODYNAMICS; HEART OUTPUT; HEART RIGHT VENTRICLE ENDSYSTOLIC VOLUME; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTHROMBIN TIME; PULMONARY HYPERTENSION; RAT; SYSTOLE; THROMBUS;

ANIMALS; BLOOD COAGULATION; ENOXAPARIN; FACTOR XA; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MONOCROTALINE; MORPHOLINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; THIOPHENES; THROMBOSIS; WARFARIN;

EID: 80052907640     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr168     Document Type: Article

References (41)

1. Rhodes CJ, Davidson A, Gibbs JS, Wharton J, Wilkins MR. Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther 2009;121:69-88.
2. Reinhart K, Salerno E, White CM. Pulmonary arterial hypertension: an overview of current pharmacologic treatment. Conn Med 2008;72:531-534.
3. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-1928. (Pubitemid 46981654)
4. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:35S-62S. (Pubitemid 38932341)
5. Hassoun PM, Thompson BT, Steigman D, Hales CA. Effect of heparin and warfarin on chronic hypoxic pulmonary hypertension and vascular remodeling in the guinea pig. Am Rev Respir Dis 1989;139:763-768. (Pubitemid 19084403)
6. Hampl V, Archer SL, Bach R, Nelson DP, Weir EK. Chronic hypoxic pulmonary hypertension. Is thrombin involved? Am Rev Respir Dis 1993;148:1043-1048. (Pubitemid 23301228)
7. Hales CA, Kradin RL, Brandstetter RD, Zhu YJ. Impairment of hypoxic pulmonary artery remodeling by heparin in mice. Am Rev Respir Dis 1983;128:747-751. (Pubitemid 13014131)
8. Kentera D, Susic D, Zdravkovic M. Hypotensive effect of heparin on experimental chronic pulmonary hypertension in rats. Basic Res Cardiol 1985;80:142-146.
9. Hu LM, Geggel R, Davies P, Reid L. The effect of heparin on the haemodynamic and structural response in the rat to acute and chronic hypoxia. Br J Exp Pathol 1989;70: 113-124. (Pubitemid 19135743)
10. Hassoun PM, Thompson BT, Hales CA. Partial reversal of hypoxic pulmonary hypertension by heparin. Am Rev Respir Dis 1992;145:193-196.
11. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-2775. (Pubitemid 351930851)
12. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-39.
13. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-2786. (Pubitemid 351930852)
14. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-1680.
15. Berry CN, Girard D, Lochot S, Lecoffre C. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time. Br J Pharmacol 1994;113:1209-1214. (Pubitemid 24364400)
16. Sato K, Taniuchi Y, Kawasaki T, Hirayama F, Koshio H, Matsumoto Y. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats. Eur J Pharmacol 1998;347:231-236. (Pubitemid 28234462)
17. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005;3:514-521. (Pubitemid 41632877)
18. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115: 2811-2821. (Pubitemid 41434408)
19. Klein M, Schermuly RT, Ellinghaus P, Milting H, Riedl B, Nikolova S et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 2008; 118:2081-2090.
20. Weinz C, Buetehorn U, Daehler HP, Kohlsdorfer C, Pleiss U, Sandmann S et al. Pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-in rats and dogs. Xenobiotica 2005;35:891-910. (Pubitemid 41759174)
21. Colas Linhart N, Laforest MD, Guiraud-Vitaux F, Gardin I, Petiet A, Berthelot JL et al. Pharmacokinetics and tissue distribution of 99mTc-labelled enoxaparin in the rat: evaluation of dosimetry parameters. Biomed Pharmacother 1990;44:317-323. (Pubitemid 20318144)
22. Schermuly RT, Pullamsetti SS, Kwapiszewska G, Dumitrascu R, Tian X, Weissmann N et al. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation 2007;115:2331-2339. (Pubitemid 46685901)
23. Klein PS. Letter by Klein regarding article, 'Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study'. Circulation 2008;117:e21.
24. Dony E, Lai YJ, Dumitrascu R, Pullamsetti SS, Savai R, Ghofrani HA et al. Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/ 4 inhibition. Eur Respir J 2008;31:599-610.
25. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159. (Pubitemid 17064313)
26. White SM, Wagner JG, Roth RA. Effects of altered platelet number on pulmonary hypertension and platelet sequestration in monocrotaline pyrrole-treated rats. Toxicol Appl Pharmacol 1989;99:302-313. (Pubitemid 19201318)
27. Sobin SS, Tremer HM, Hardy JD, Chiodi HP. Changes in arteriole in acute and chronic hypoxic pulmonary hypertension and recovery in rat. J Appl Physiol 1983;55: 1445-1455. (Pubitemid 14231449)
28. White SM, Roth RA. Pulmonary platelet sequestration is increased following monocrotaline pyrrole treatment of rats. Toxicol Appl Pharmacol 1988;96:465-475. (Pubitemid 19023784)
29. Fasules JW, Stenmark KR, Henson PM, Voelkel NF, Reeves JT. Neither anticoagulant nor nonanticoagulant heparin affects monocrotaline lung injury. J Appl Physiol 1987;62: 816-820. (Pubitemid 17066649)
30. Al Ansari E, Du HK, Yu L, Ochoa CD, Garg HG, Quinn DA et al. Low-molecular-weight heparin inhibits hypoxic pulmonary hypertension and vascular remodeling in guinea pigs. Chest 2007;132:1898-1905.
31. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989;80:1198-1206.
32. Shitrit D, Bendayan D, Bar-Gil-Shitrit A, Huerta M, Rudensky B, Fink G et al. Significance of a plasma D-dimer test in patients with primary pulmonary hypertension. Chest 2002;122:1674-1678. (Pubitemid 35366081)
33. Tournier A, Wahl D, Chaouat A, Max JP, Regnault V, Lecompte T et al. Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension. Thromb Res 2010;126:e418-e422.
34. Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J 2006;28:999-1004. (Pubitemid 46331971)
35. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
36. Eisenberg PR, Lucore C, Kaufman L, Sobel BE, Jaffe AS, Rich S. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 1990;82:841-847. (Pubitemid 20316735)
37. Huber K, Beckmann R, Frank H, Kneussl M, Mlczoch J, Binder BR. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 1994;150:929-933. (Pubitemid 24318015)
38. Grunig E, Ehlken N, Nagel Ch. Anticoagulation in pulmonary arterial hypertension. Hamostaseologie 2008;28:225-230.
39. Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J 1998;12:1446-1449. (Pubitemid 29011445)
40. Campian ME, Hardziyenka M, Michel MC, Tan HL. How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol 2006;373:391-400. (Pubitemid 44401410)
41. Hayashi Y, Lalich JJ. Renal and pulmonary alterations induced in rats by a single injection of monocrotaline. Proc Soc Exp Biol Med 1967;124:392-396.